Skip to main content
. 2018 Oct 2;10:258. doi: 10.3389/fnagi.2018.00258

Figure 1.

Figure 1

Risk of cognitive impairment of patients receiving NOACs and vitamin K Antagonists (VKAs) or acetylsalicylic acid using fixed-effects model (A) or random-effects model (B). HR indicates Hazard ratio; 95%CI indicates 95% confidence interval.

HHS Vulnerability Disclosure